DarioHealth Corp. activated its new conversational AI companion, DarioIQ, within the Dario Health app on December 10, 2025 for a cohort of hypertension members. The feature delivers real‑time biometric interpretation, personalized guidance, and proactive interventions that run in parallel with the company’s existing human coaching framework.
The launch comes amid a challenging financial quarter. In Q3 2025, DarioHealth reported revenue of $5.0 million, down 32% from $7.4 million in Q3 2024, and an earnings‑per‑share loss of $2.96 versus a consensus estimate of $0.19. The decline was driven by the non‑renewal of a large national health‑plan contract and a deliberate shift from one‑time revenue streams to a recurring‑revenue model, which increased operating costs in the short term. Gross margins improved to 60% GAAP and 80% for the B2B2C segment, reflecting higher‑margin recurring contracts.
Senior Vice President Galya Gorodinsky said the hypertension focus allows DarioHealth to validate the full end‑to‑end experience—device data interpretation, adaptive conversational guidance, and safety guardrails—before scaling to other chronic conditions. Chief Operating Officer Lara Dodo emphasized that DarioIQ is designed to complement, not replace, human coaching, and that the direct‑to‑consumer launch will provide learning data to refine the AI before broader deployment.
The AI launch aligns with DarioHealth’s broader GenAI roadmap, which targets diabetes, weight management, behavioral health, musculoskeletal conditions, and sleep disorders. By starting with hypertension, the company can refine the user experience, validate safety, and demonstrate value to B2B2C partners such as employers, health plans, and pharmaceutical clients. The move is intended to support a high‑margin B2B2C growth strategy and to increase recurring revenue streams in the coming quarters.
Overall, the introduction of DarioIQ marks a significant step in DarioHealth’s digital‑health strategy, combining AI‑driven personalization with proven coaching. While the company faces short‑term revenue pressure, the new feature positions it to capture a larger share of the growing chronic‑condition management market and to strengthen its recurring‑revenue pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.